-- 苏州泽尔根生物制药（SHA:688266）周五向上海证券交易所提交的文件显示，其重组人促甲状腺激素α注射液的三期临床试验已达到预设的主要终点，即在无远处转移的分化型甲状腺癌患者中，放射性碘残留消融治疗的效果不劣于传统甲状腺激素停药疗法。 该研究表明，重组人促甲状腺激素α注射液的疗效不劣于传统甲状腺激素停药疗法。 该公司计划就上述适应症提交该药物的生物制品许可申请。 苏州泽尔根生物制药的股价在近期交易中下跌了3%。
Related Articles
Asia
Beijing Foyou Pharma Wins China Nod for Rapid-Dissolve Hypertension Tablet
Beijing Foyou Pharma (SHA:601089) received a drug registration certificate for olmesartan medoxomil orally disintegrating tablets from China's National Medical Products Administration, according to a Shanghai bourse filing on Friday.The drug is used for the treatment of hypertension.
$SHA:601089
Asia
Australian Shares End Lower; Macquarie Group Posts Higher Fiscal Year 2026 Earnings, Revenue
Australian shares ended lower on Friday as oil prices rose amid clashes between US and Iranian forces.The S&P/ASX 200 Index fell 1.51%, or 133.70 points, to close at 8,744.40.Brent crude oil futures rose over 1% to trade around $101 per barrel. US President Donald Trump said that the ceasefire between Iran and the US was still in effect despite the clashes, while Iran said the situation had returned to normal, according to a Reuters report.In company news, Macquarie Group (ASX:MQG) reported Friday fiscal year earnings of AU$12.669 per share, up from AU$9.755 a year earlier. Revenue from ordinary activities for the 12 months ended March 31 was AU$19.48 billion, compared with AU$17.21 billion a year earlier. Its shares fell 1% on market close.News Corp (ASX:NWS) reported fiscal third-quarter adjusted earnings of $0.21 per share, up from $0.17 a year earlier. Revenue for the quarter ended March 31 was $2.19 billion, up from $2.01 billion a year ago. Its shares closed down 8%, earlier reaching a two-year low point. Its shares closed up 3%.Lastly, QBE Insurance Group (ASX:QBE) reported first-quarter gross written premiums of $9.2 billion, up 11% from $8.3 billion a year earlier. The company maintained its full-year guidance for gross written premium growth in the mid-single digits and a combined operating ratio of nearly 93%. Its shares fell 1% on market close.
$^AXJO$ASX:MQG$ASX:NWS$ASX:QBE
US Markets
OCBC Profit Rises in Q1 as Wealth, Insurance Income Offset Margin Pressure
Oversea-Chinese Banking Corp. or OCBC (SGX:O39), posted a 5% rise in first-quarter attributable profit as record non-interest income, led by solid growth in wealth management, cushioned the impact of thinning lending margins in a declining interest rate environment.Net profit attributable to equity holders came in at SG$1.97 billion, up from SG$1.88 billion a year earlier, according to the company's earnings published Friday.Earnings per share rose to SG$1.76, compared with SG$1.67 in the year-ago period. Analysts polled by Visible Alpha had projected EPS of SG$0.43 for the period.Total income rose 5% to SG$3.83 billion from SG$3.66 billion, as non-interest income jumped 23% to SG$1.61 billion from SG$1.31 billion a year earlier.Net interest income, however, declined 5% year over year to SG$2.22 billion from SG$2.35 billion. Analysts polled by Visible Alpha had projected net interest income of SG$2.30 billion."The Group's solid Q1 performance was underpinned by record non-interest income, led by strong growth in wealth management." "Operating expenses were well managed, with cost-to-income ratio below 40%. Loans and deposits were higher, supported by continued momentum in strategic growth areas," the lender said.OCBC added that its acquisition of HSBC's wealth business in Indonesia fits well into its "Next Frontier strategy" as the lender looks to build up its wealth business in Indonesia.Despite the strong performance, OCBC issued a cautious outlook regarding the global landscape, highlighting that global conditions remain uncertain amidst persistent geopolitical tensions and elevated inflation risks.The lender noted that the near-term outlook will depend on the evolution of the war in the Middle East and its potential impact on energy supply and pricing.However, OCBC reaffirmed that it remains "well positioned to navigate uncertainties and deliver sustainable long-term value."
$SGX:O39